N-乙酰基转移酶10基因与急性髓系白血病病人预后的关系分析

宋辉; 于艺冰; 郭媛媛

doi:10.13898/j.cnki.issn.1000-2200.2023.02.006

N-乙酰基转移酶10基因与急性髓系白血病病人预后的关系分析

Analysis of the relationship between N-acetyltransferase 10 gene and prognosis in patients with acute myeloid leukemia

摘要

摘要:
目的探究N-乙酰基转移酶10（N-acetyltransferase 10，NAT10）与急性髓系白血病（acute myeloid leukemia，AML）预后的关系。
方法选取2015年9月至2018年1月收治的84例初治AML病人（初治组）、20例复发AML病人（复发组）、20例AML完全缓解病人（缓解组）和20名健康人（对照组）为研究对象。用RT-PCR检测受试者骨髓单个核细胞中NAT10 mRNA的表达。ROC曲线分析NAT10 mRNA早期诊断AML的价值，计算曲线下面积（AUC）、灵敏度和特异度。以NAT10 mRNA中位表达水平将84例AML病人分为高表达组和低表达组，比较2组病人的生存预后。
结果初治组和复发组骨髓单个核细胞中NAT10 mRNA相对表达量均高于缓解组和对照组（P < 0.05~P < 0.01）。NAT10 mRNA早期诊断AML的AUC为0.827（95%CI：0.723~0.930，P < 0.01），灵敏度和特异度分别为83.6%和82.6%。COX多因素分析显示，FLT3-ITD/TKD突变和NAT10 mRNA高表达是AML病人总生存时间的独立影响因素（P < 0.05），FLT3-ITD/TKD突变和NAT10 mRNA高表达也是AML病人无事件生存时间的独立影响因素（P < 0.05）。NAT10 mRNA高表达组中位总生存时间为4个月，低于低表达组的10个月（P < 0.01）。NAT10 mRNA高表达组中位无进展生存时间为3个月，低于低表达组的8个月（P < 0.01）。
结论NAT10对AML的早期诊断及病情评估可能有一定价值，NAT10 mRNA高表达与AML病人的不良生存预后有关。

Abstract:
ObjectiveTo explore the relationship between N-acetyltransferase 10(NAT10) and prognosis of patients with acute myeloid leukemia(AML).
MethodsA total of 84 patients with newly treated AML(initial treatment group), 20 patients with relapsed AML(relapsed group), 20 patients with complete remission of AML(remission group) and 20 healthy people(control group) from September 2015 to January 2018 were investigated.The expression level of NAT10 mRNA in bone marrow mononuclear cells was detected by RT-PCR.The receiver operator characteristic(ROC) curve was used to analyze the value of NAT10 mRNA in the early diagnosis of AML, and the area under the curve(AUC), sensitivity and specificity were calculated.Eighty-four AML patients were divided into the high expression group and low expression group according to the expression level of NAT10 mRNA, and the survival prognosis between two groups was compared.
ResultsThe relative expression levels of NAT10 mRNA in bone marrow mononuclear cells in initial treatment group and recurrence group were higher than that in remission group and control group(P < 0.05 to P < 0.01).The AUC of NAT10 mRNA in the early diagnosis of AML was 0.827(95%CI: 0.723-0.930, P < 0.01), and the sensitivity and specificity were 83.6% and 82.6%, respectively.The results of COX multivariate analysis showed that the FLT3-ITD/TKD mutation and high expression of NAT10 mRNA were the independent influencing factors of the overall survival time and event-free survival time in AML patients(P < 0.05).The median overall survival time in the high NAT10 mRNA expression group was 4 months, which was lower than that of 10 months in low NAT10 mRNA expression group(P < 0.01).The median progression-free survival time in the group with high NAT10 mRNA expression group was 3 months, which was lower than that of 8 months in low NAT10 mRNA expression group(P < 0.01).
ConclusionsNAT10 may have some value in the early diagnosis and evaluation of AML.The high expression of NAT10 mRNA is related to the poor survival and prognosis of AML patients.

HTML全文

参考文献(23)

施引文献

资源附件(0)